Dr. Bruce D Latham, D.O. Family Medicine Medicare: May Accept Medicare Assignments Practice Location: 66 Main St, Conway, NH 03818 Phone: 603-901-1042 Fax: 603-901-1092 |
News Archive
Cerenis Therapeutics SA (Cerenis), a biopharmaceutical company specializing in the research and development of novel therapies based on the metabolism of HDL (the "good" cholesterol) to treat cardiovascular and other metabolic diseases, announced today it has raised €40 million in the first close of its series C financing. In this round €20 million came from the Fund for Strategic Investment (FSI) with an additional €20 million coming from the existing investors: Sofinnova Partners, HealthCap, Alta Partners and TVM Capital, EDF Ventures, OrbiMed and DAIWA Corporate Investment.
When 225 researchers from around the world convened in Miami to exchange the latest on β amyloid positron emission tomography in January, there was a palpable sense of urgency. At the 6th Annual Human Amyloid Imaging (HAI) Conference, the possibility of approval, potentially within months, of the first amyloid-scanning compound for clinical use hung over the room.
Sam Sanderson, Ph.D., a research associate professor in the UNMC College of Pharmacy, recently secured an R01 grant from the National Institutes of Health to find a workable solution to the problem of antibiotic resistance.
A novel strategy to hopefully beat into oblivion one of the most aggressive forms of acute myelogenous leukemia combines the strengths of some of the newest leukemia agents, researchers say.
Long-term research that was initiated at UCLA's Jonsson Comprehensive Cancer Center on lymphatic mapping and sentinel-node biopsy, techniques for detecting the earliest spread (metastasis) of melanoma, the deadliest form of skin cancer, has confirmed that these techniques significantly prolong patients' disease-free and melanoma-specific survival over the traditional observational "watch and wait" techniques.
› Verified 9 days ago